Studies in humans and mice have emphasized that different DC subsets are endowed with specialized functions, and a good vaccine should target these subsets in a coordinated way. The current studies provide the basis for a new approach relying on BDCA3 + DCs as antitumor and antiviral vaccines, as they seem to be a key subset for cross-presentation of cell-associated antigens. Further characterization of these DCs will enable rational approaches to target them to improve vaccine efficacy.
Although Poulin et al. 7 were able to generate BDCA3 + DCs from cord blood hematopoietic stem cells, their yield was too low to be practical for using this method to generate enough cells for vaccination. Alternative vaccination strategies such as the delivery of tumor antigens in vivo to specific DC subsets could also be employed (Fig. 1b) . Given the restricted expression of DNGR-1 on BDCA3 + DCs and data showing that a DNGR-1-targeted antigen is efficiently cross-presented to CD8 + T cells in mice 8 , this receptor might be used to target tumor-associated antigens to endogenous BDCA3 + DCs along with activation signals such as poly I:C. In the same way, the selective XCR1 expression on only these DCs makes this chemokine receptor another interesting target for the delivery of vaccines to crosspresenting DCs 4 .
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Although we are inclined to view the nervous and immune systems of the body as separate entities, the reality is far more complex. At the molecular level, crosstalk between the nervous and immune systems has been well documented. Many molecules and mediators are common to both, and substances produced by the immune system act on the nervous system and vice versa. As an example, the cytokine interleukin-1 (IL-1), which is fundamental to the process of inflammation, was discovered largely because of its role in immunoreactive innervation of the hypothalamus to elicit fever 1 . Conversely, the neurotransmitter nitric oxide is also produced by cells of the immune system and has a role in inflammation and immunomodulation 2, 3 .
In this issue of Nature Medicine, Fallarino et al. 4 add the neurotransmitter glutamate to the list of substances that participate in crosstalk between the nervous and immune systems. High amounts of glutamate are found in the brain of individuals with multiple sclerosis, and whereas this is widely thought to contribute to neurotoxicity, the authors now present an alternative possibility-a role for glutamate in driving a regulatory T cell response that ameliorates neuroinflammation in a mouse model of this paralyzing disease. They show that this increase in regulatory T cells is mediated by the metabotropic glutamate receptor-4 (mGluR4) expressed on dendritic cells (DCs), a cell type crucial for supporting an immune response. Their data suggest that glutamate may have a protective role in inflammatory neurodegenerative diseases.
Glutamate is a highly abundant excitatory neurotransmitter and is essential for many aspects of normal brain function such as learning and memory 5 . Its actions are mediated by ionotropic (ion channel-forming) and by metabotropic (G protein-activating) glutamate receptors 5 . In excess, however, glutamate is harmful and causes neuronal death through a massive calcium influx via ionotropic glutamate receptor channels, with consequent damage to mitochondria and activation of proapoptotic genes. Glutamate toxicity occurs as part of the ischemic cascade associated with spinal cord injury, stroke, traumatic brain injury and in various diseases of the central nervous system, including Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease and multiple sclerosis 5 .
The adaptive immune response is orchestrated by antigen-specific T cells, which differentiate after activation into one of several functionally distinct T 'helper' lineages known as T H 1, T H 2 and T H 17 (ref. 6 ). Each produces a distinct assortment of cytokines and chemokines under control of their respective lineagespecific transcription factors T-bet, GATA3 and ROR-γt. Whereas their role is to protect us from various types of pathogens, they can also be involved in tissue pathology 6 . For example, T H 2 cells are involved in allergy and asthma, and T H 1 cells, and even more so T H 17 cells, are involved in autoimmune diseases such as experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis induced in mice by immunization with an antigenic peptide derived from brain myelin.
T cells respond to their antigen displayed on the surface of DCs, which also express costimulatory molecules and polarizing cytokines, and direct the responding T cells to adopt
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Elevated amounts of glutamate, which acts as a neurotransmitter but is also a neurotoxin, are a hallmark of the auto immune neurological disease multiple sclerosis and may contribute to its pathology. The discovery that a receptor for glutamate can inhibit the development of autoimmunity and protect from neuroinflammation in a mouse model of multiple sclerosis suggests that glutamate may also have a protective role and that its receptor may represent a therapeutic target (pages 897-902).
of Parkinson's disease in which a mGluR4 enhancer is used to reduce glutamate release in the brain 8 . If this therapy proves effective, could hitherto unknown immunological effects be involved? Could suppression of T H 17 responses, important in antimicrobial defense, be an unwanted side effect of this treatment? Answers to these questions could have implications not only for treatment of conditions associated with glutamate toxicity, but also for a broad range of debilitating autoimmune disorders that have been linked to aberrant T H 17 responses, including rheumatoid arthritis, psoriasis, inflammatory bowel disease and uveitis 9, 10 .
The study by Fallarino et al. 4 , and others to come, will continue to blur the distinctions between the signals driving the nervous, approved therapies for autoimmune neurological diseases have variable efficacy, major side effects and can only slow, and not stop, the neurodegenerative process 7 . Although the data of Fallarino et al. 4 are promising, more studies are needed to clarify issues relevant to the clinical setting. Protection, for instance, does not seem to be maintained after treatment cessation, despite the development of T reg cells-a disappointing result. Further treatment, however, is not required to maintain T reg cellmediated protection upon transfer of these cells to new recipients 4 . Whereas mGluR4 stimulation is effective in disease prevention, it is unclear whether it would be effective after the onset of clinical symptoms.
This study also raises questions relevant to an ongoing clinical trial for treatment a particular lineage (Fig. 1) . For example, IL-12 and IL-27 produced by DCs will specifically drive T-bet expression in the T cell, promoting a T H 1 response dominated by the cytokine interferon-γ. Alternatively, release of transforming growth factor-b (TGF-b), IL-1, IL-6 and IL-23 leads to ROR-γt expression by the T cells and differentiation toward the T H 17 lineage. Expression of TGF-b in the absence of IL-6 also directs the induction of another T cell transcription factor known as FoxP3. FoxP3 can directly suppress expression of ROR-γt and causes the T cells to adopt a regulatory phenotype, yielding T regulatory cells (T reg cells) that inhibit inflammatory effector T cells.
Through the expression of these different cytokines, DCs act as master regulators of the immune response, controlling not only whether an inflammatory immune response will occur, but also its nature, depending on the T cell lineage that is induced 6 . What environmental cues control the function and decision making of these master regulators? Fallarino et al. 4 show that one of these cues is glutamate, which acts through metabotropic glutamate receptors that are expressed by DCs.
Previous studies have examined the effect of various neurotransmitters on the immune response, but they preceded the identification of T H 17 cells as pathogenic effectors and largely ignored a role for DCs. Armed with the information now available regarding the T H 17 response, the authors used a combination of mice deficient in mGluR4 and specific allosteric compounds that enhance mGluR4 receptor signaling in wild-type mice to examine the role of this receptor in EAE 4 . They found that mice deficient in mGluR4 developed exacerbated disease with a higher mortality, whereas enhanced glutamate signaling through mGluR4 ameliorated disease and favored the induction of T reg cells at the expense of T H 17 development 4 . Interestingly, although high receptor expression was found on T cells and on DCs, the protective effect of mGluR4 signaling was mediated entirely by DCs and occurred via mGluR4's inhibitory effect on intracellular activation of cAMP. Inhibition of cAMP activation prevents IL-6 and IL-23 production and skews the DC cytokine response to a profile favoring induction of T reg cells, which turn out to be responsible for the resulting protection from EAE in mice-as shown by the ability of T cells obtained from mice protected by mGluR4 stimulation to transfer protection to untreated recipients, which was reversed by removal of T reg cells.
Notably, human DCs also expressed mGluR4, and activation of this receptor with the same allosteric stimulator used in mice had comparable effects in human DCs. Currently Figure 1 Glutamate activation of mGluR4 signaling in dendritic cells prevents the production of IL-6 and IL-23, favoring the development of T reg cells over T H 17 cells in EAE. In the absence of mGluR4, DCs respond to an inflammatory signal such as LPS by upregulating both T H 1-specific (IL-12 and IL-27) and T H 17-specific (IL-6 and IL-23) cytokines through different pathways. Transcription of IL-6 and IL-23 is induced via the production of cAMP, which is catalyzed from ATP by the enzyme adenylyl cyclase, and, in turn, activates downstream mediators such as protein kinase A (PKA), which leads to gene expression. These cytokines, along with TGF-b and IL-1, induce the transcription factor ROR-γt in the responding T cell, upregulating T H 17-specific cytokines and the IL-23 receptor, which is required later for maintenance of the T H 17 phenotype. IL-6 directly suppresses Foxp3, leading to the promotion of T H 17 at the expense of T reg cells and the development of neuroinflammation. Fallarino et al. 4 show that activation of mGluR4 by glutamate inhibits adenylyl cyclase and the production of cAMP, preventing expression of IL-6 and IL-23. In their absence, Foxp3 is upregulated by the activating T cell in the presence of TGF-b and blocks T H 17 differentiation by direct inhibition of ROR-γt, tipping the balance toward a neuroprotective response. The T H 1 response is unaffected by this process, and IL-27 and interferon-γ (IFN-γ) also contribute to the promotion of T reg cell differentiation through inhibition of ROR-γt. immune and endocrine systems, revealing unknown therapeutic potential and also highlighting the consequences that perturbing one of them may have on the others.
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The immune system has a profound effect on the development of cancers. Immunosurveillance mechanisms can destroy cells that are on the verge of malignant transformation. But this may ultimately select for cancer cells that are capable of avoiding or subverting the anticancer immune attack, fostering tumor development 1 . Once the tumors have established, immune escape-the selection of cancer cell variants that are not recognized by the immune system-and immunosubversion-the active suppression of immune effectors-facilitate tumor progression and reduce the efficacy of anticancer therapies 2 . Immune responses not only dictate the success of immunotherapies, such as anticancer vaccination, but also are probably important for conventional chemotherapies that, at least in some cases, must induce immune activation to be optimally efficient 3 .
In this issue of Nature Medicine, Herber et al. 4 reveal how the host immune system can be compromised during cancer. The authors find that an increase in the lipid content of dendritic cells (DCs)-the first-line effectors of the innate immune system that initiate cellular immune response by presenting antigens to T lymphocytes-diminishes their capacity to present antigens from tumor cells and to activate effector T cells of the immune system. The authors demonstrate that normalization of lipid levels in DCs in mice could enhance the effect of cancer vaccines, bringing us one step closer to more effective cancer immunotherapy.
In mice bearing a variety of cancers, such as mammary and colon carcinomas or thymomas, DCs that are located in the proximity of tumors (in the tumor bed or the draining lymph node) as well as those located at a distance (in the peripheral blood or in the spleen) contain a higher amount of lipids, especially triglycerides, such as triacylglycerol (TAG). The intracellular accumulation of lipid droplets is particularly apparent in the two subsets of DCs that are reputed to be efficient in tumor antigen presentation, namely CD11c + CD8a + and conventional (CD11c + CD11b + B220 -) DCs, but not in plasmacytoid (CD11c + CD11c -B220 -) DCs, considered to be tolerogenic 5 . More important, DCs from individuals with head and neck cancer, non-small-cell lung or renal cancer also show an increase in intracellular lipids 4 , suggesting that this is a general phenomenon in human malignancies. This observation brings about interesting questions about why DCs accumulate lipids in tumor-bearing individuals and how the increased triglyceride content in DCs affects their immune role of recognizing tumor cells during cancer.
Herber et al. 4 addressed how lipids accumulate in DCs by studying the effect of conditioned media from tumor explants on DCs. They showed that exposure to these tumor explant supernatants causes DCs to upregulate one particular scavenger receptor, Msr1 (also known as CD204 or SRA), which can interact with lipoproteins to mediate lipid uptake (Fig. 1) . But Msr1 is also known for its capacity to antagonize immunostimulatory signals mediated by Toll-like receptor 4 (ref. 6 ). In the current study, Msr1 was also overexpressed in the fraction of DCs that increase their lipid content in tumor-bearing mice 4 . Neutralization of Msr1 with specific antibodies in vitro abolished the lipid accumulation in DCs in response to tumor explant supernatants. DCs from mice deficient in Msr1 did not accumulate lipids when they were transferred into wild-type tumor-bearing mice, suggesting that the lipid increase in DCs is driven by Msr1 upregulation. The factors secreted by tumor cells that induce Msr1 in DCs are still elusive. Their identification might yield promising targets for the development of strategies to restore anticancer immune responses.
The main role of DCs is to capture proteins from infected, stressed or dying cells, including tumor cells, and process them into antigenic peptides, which are then incorporated into major histocompatibility complex (MHC) proteins. After antigen recognition and processing, DCs can expose antigenic peptide-MHC complexes at the cell surface to stimulate specific T cells, a crucial step to launch productive immune responses 5 . Herber et al. 4 studied the antigen recognition, processing and presentation capabilities of lipid-laden DCs and concluded that they were inefficient in the processing and loading of protein antigens into MHC complexes. Although it remains unknown how the accumulation of TAG interferes with these functions, the connection between lipid accumulation and DC dysfunction represents an exciting new concept in the downregulation of the immune system during cancer.
In a further twist of the story, Herber et al. 4 could lower triglyceride levels in DCs by pharmacologically inhibiting their synthesis with a specific inhibitor of acetyl-CoA carboxylase, 5-(tetradecycloxy)-2-furoic acid (TOFA). Treatment with TOFA prevented the accumulation of lipids in DCs in vitro upon exposure to tumor explant supernatants or in vivo when DCs were obtained from tumor-bearing mice treated with TOFA 4 . This suggests that active
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Cancers can compromise the capacity of the host immune system to recognize tumor antigens. Recent findings now show that increased accumulation of lipids in dendritic cells in tumors can impair presentation of tumor antigenswhich is crucial for activation of the immune system-providing a conceptual framework that may help increase the efficacy of therapeutic vaccines (pages 880-886).
